By covalently modifying cysteine residues on key signaling proteins such as MEK and ERK, S-nitrosylation sustains aberrant MAPK pathway activation and promotes melanoma cell proliferation and survival, even in the presence of targeted therapies. The gene discussed is MAP2K7; the disease is melanoma.